Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 7

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 7
---
(56,275) 
     (128,757)
  
    Net cash used in operating activities 
     (3,570,847) 
     (5,884,842)

    Cash Flows from Investing Activities 

    Purchases of fixed assets 
     (17,280) 
     (16,000)
  
    Proceeds from sale of fixed assets 
     -  
     3,204 
  
    Net cash used in investing activities 
     (17,280) 
     (12,796)

    Cash Flows from Financing Activities 

    Proceeds from issuance of common stock 
     1,152,684  
     1,148,470 
  
    Proceeds from warrant issuances and exercises 
     -  
     5,368,363 
  
    Proceeds from issuance of cashless warrants 
        
     1,320,568 
  
    Repayment of loan 
     -  
     (28,484)
  
    Net cash provided by financing activities 
     1,152,684  
     7,808,917 

    Net increase (decrease) in cash 
     (2,435,443) 
     1,911,280 

    Cash, beginning of period 
     3,229,480  
     2,833,907 

    Cash, end of period 
    $794,036  
    $4,745,187 

    Supplemental disclosures of cash items 

    Interest paid 
    $42,988  
    $23,211 
  
    Income tax paid 
    $-  
    $- 

    Supplemental disclosures of non-cash items 

    Stock dividend payable 
    $-  
    $(5,232)
  
    Right of use asset 
    $491,363  
    $229,771 
  
    Lease liability 
    $525,328  
    $237,162 
  
    Cashless Warrants 
        
     3,071,252 

The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.

5

ENDRA Life Sciences Inc.

Notes to Condensed Consolidated Financial Statements

For the nine months ended September 30, 2025
and 2024

(Unaudited)

Note 1 - Nature of the Business